Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
Top Cited Papers
- 14 November 2005
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 366 (9500), 1849-1861
- https://doi.org/10.1016/s0140-6736(05)67667-2
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic SyndromeArchives of Internal Medicine, 2005
- Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)American Journal of Kidney Diseases, 2005
- Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosisAtherosclerosis, 2004
- Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetesBMJ, 2003
- Dynamic balanced randomization for clinical trialsStatistics in Medicine, 1993
- WHO clofibrate/cholesterol trial: clarificationsThe Lancet, 1992
- LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart StudyDiabetes Care, 1992
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabeticsAtherosclerosis, 1985